Cencora, Inc. (COR) Gross Margin: 3.47%
Is Cencora, Inc.’s gross margin high or low?
Cencora, Inc.'s gross margin of 3.47% is 17% above its 5-year average of 2.95%, near the high end of its 5-year range (2.52%–3.47%).
As of Saturday, June 13, 2026. 13.40% above its 12-month average of 3.06%.
COR Gross Margin Chart
COR Average Gross Margin Chart
COR Current vs Average Gross Margin Chart
COR Gross Margin Metrics
GROSS MARGIN
3.47%
GROSS MARGIN AVG TTM
3.06%
GROSS MARGIN AVG 3Y
3.07%
GROSS MARGIN AVG 5Y
2.95%
GROSS MARGIN AVG 10Y
2.76%
GROSS MARGIN AVG 15Y
2.77%
GROSS MARGIN AVG 20Y
2.86%
CURRENT VS TTM AVG
+13.40%
CURRENT VS 3Y AVG
+13.12%
CURRENT VS 5Y AVG
+17.49%
CURRENT VS 10Y AVG
+25.85%
CURRENT VS 15Y AVG
+25.13%
CURRENT VS 20Y AVG
+21.17%
COR Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 3.47% | 3.06% | 3.07% | 2.95% |
| Becton, Dickinson and Company (BDX) | $52.98B | 46.48% | 45.33% | 44.44% | 44.19% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 84.55% | 85.74% | 85.09% | 84.57% |
| Humana Inc. (HUM) | $45.53B | 14.01% | 14.54% | 16.14% | 17.03% |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 62.05% | 61.42% | 60.55% | 59.83% |
| Agilent Technologies, Inc. (A) | $36.67B | 53.00% | 53.36% | 52.95% | 53.14% |
| Zoetis Inc. (ZTS) | $33.36B | 70.75% | 69.79% | 68.91% | 68.46% |
| Centene Corporation (CNC) | $32.19B | 14.93% | 11.28% | 11.33% | 11.71% |
| Medline Inc. (MDLN) | $30.96B | 24.04% | 25.55% | 23.71% | 23.71% |
| Cigna Corporation (CI) | $78.83B | 9.30% | 9.98% | 11.47% | 12.36% |
Gross Margin Analysis
Gross Margin
3.5%
(Revenue - COGS) / Revenue
Cencora, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. Gross Margin FAQ
- What is the gross margin for Cencora, Inc. (COR)?
- The gross margin for COR stock is 3.47%.
- Is Cencora, Inc.'s gross margin high or low?
- Cencora, Inc.'s gross margin of 3.47% is 17% above its 5-year average of 2.95%, near the high end of its 5-year range (2.52%–3.47%).
- What is the TTM average gross margin for Cencora, Inc. (COR)?
- The TTM average gross margin for COR stock is 3.06%.
- What is the 3Y average gross margin for Cencora, Inc. (COR)?
- The 3Y average gross margin for COR stock is 3.07%.
- What is the 5Y average gross margin for Cencora, Inc. (COR)?
- The 5Y average gross margin for COR stock is 2.95%.
- What is the 10Y average gross margin for Cencora, Inc. (COR)?
- The 10Y average gross margin for COR stock is 2.76%.
- What is the 15Y average gross margin for Cencora, Inc. (COR)?
- The 15Y average gross margin for COR stock is 2.77%.
- What is the 20Y average gross margin for Cencora, Inc. (COR)?
- The 20Y average gross margin for COR stock is 2.86%.
Cencora, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-09-30 | 3.16% |
| 2024-09-30 | 2.96% |
| 2023-09-30 | 2.96% |
| 2022-09-30 | 3.19% |
| 2021-09-30 | 2.93% |
| 2020-09-30 | 2.52% |
| 2019-09-30 | 2.52% |
| 2018-09-30 | 2.45% |
| 2017-09-30 | 2.71% |
| 2016-09-30 | 2.57% |
| 2015-09-30 | 2.36% |
| 2014-09-30 | 2.32% |
| 2013-09-30 | 2.64% |
| 2012-09-30 | 3.16% |
| 2011-09-30 | 3.03% |
| 2010-09-30 | 2.89% |
| 2009-09-30 | 2.81% |
| 2008-09-30 | 2.78% |
| 2007-09-30 | 3.33% |
| 2006-09-30 | 3.44% |
| 2005-09-30 | 3.41% |
| 2004-09-30 | 3.86% |
| 2003-09-30 | 4.53% |
| 2002-09-30 | 4.48% |
| 2001-09-30 | 4.32% |
| 2000-09-30 | 4.47% |
| 1999-09-30 | 4.85% |
| 1998-09-30 | 4.88% |
| 1997-09-30 | 4.98% |
| 1996-09-30 | 5.49% |
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch